Last updated: February 15, 2026
Overview of the Drug
NDC 00023-6151 is marketed as Cosentyx (secukinumab), developed by Novartis. It is an interleukin-17A inhibitor used primarily for psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
Market Size and Demand Drivers
The global psoriasis treatment market reached approximately $14.8 billion in 2022, with biologic therapies accounting for over 70%. Cosentyx holds a significant market share, estimated around 20-25% within biologics for plaque psoriasis, with sales heightening annually due to broadening indications and an expanding patient base. The following factors fuel demand:
- Increasing prevalence of psoriasis (about 2-3% of the global population) and psoriatic arthritis.
- Growing adoption of biologics as first-line treatment over traditional therapies.
- Enhanced reimbursement pathways, especially in North America and Europe.
- Expansion into new indications, such as ankylosing spondylitis.
Competitive Landscape
Key competitors include Eli Lilly’s Taltz (ixekizumab), Johnson & Johnson’s Stelara (ustekinumab), and newer entrants like Biogen’s adalimumab biosimilars. Cosentyx’s position benefits from high efficacy, once-monthly dosing, and robust safety data. Market share fluctuates with patent expirations and biosimilar entries.
Pricing Dynamics
List prices of Cosentyx vary by region and indication, with U.S. retail prices averaging approximately $6,900 per month's supply ($82,800 annually), based on wholesale acquisition cost (WAC). Reimbursed prices are typically lower due to discounts, rebates, and payor negotiations.
- U.S. list price: ~$6,900/month
- European prices: €3,000-€4,000/month ($3,290-$4,390)
- Reimbursed prices: 20-40% discount in the U.S., lower in other markets
Pricing Trends and Regulation
Pricing in the U.S. remains largely stable, with minimal decreases due to limited biosimilar competition. In Europe, price caps and national reimbursement policies influence drug costs. Patent protections last until approximately 2027-2028, after which biosimilars are expected to enter the market, creating downward pressure.
Revenue and Sales Projections
Novartis reported Cosentyx sales of $3.2 billion in 2022, up from $2.6 billion in 2021. Projected growth rate for the next five years is approximately 8-10% annually, driven by market expansion and indication growth.
- 2025 forecast: $4.4-$4.8 billion, assuming continued market share retention.
- Biosimilar entry post-2027 could reduce premium prices by an estimated 20-50%, potentially decreasing revenue by 10-20% unless market share remains stable via new indications.
Market Risks and Opportunities
Risks include patent expiry, biosimilar competition, and regulatory changes influencing pricing. Opportunities focus on expanding indications (e.g., Crohn’s disease, hidradenitis suppurativa), and geographic expansion into emerging markets.
| Pricing Projections Breakdown |
Year |
Estimated U.S. Monthly Price |
Estimated Global Average Price |
Notes |
| 2023 |
$6,900 |
$3,500 |
Current market rate |
| 2024 |
$6,850 |
$3,400 |
Slight decrease expected due to negotiations |
| 2025 |
$6,800 |
$3,300 |
Slight decline as biosimilars approach |
| 2028 |
$5,200 (post-biosimilar) |
$2,600 |
Potential decline depending on biosimilar penetration |
Conclusion
Cosentyx retains premium pricing through 2027, driven by high efficacy and patent exclusivity. Its market growth depends on indication expansion and geographic penetration. Biosimilar competition post-2027 will exert downward pressure, leading to potential price declines of 20-50% over the subsequent five years.
Key Takeaways
- NDC 00023-6151 (Cosentyx) commands a high price, averaging around $6,900/month in the U.S.
- The market is projected to grow to nearly $4.8 billion by 2025, barring biosimilar entry.
- Patent expirations beginning around 2027 will likely trigger significant price reductions.
- Expanding indications could sustain revenue streams despite biosimilar competition.
- Price erosion post-patent expiry is expected to be substantial, influencing overall market dynamics.
Frequently Asked Questions
-
What is the main driver of Cosentyx's pricing power?
Its efficacy, dosing convenience, and limited competition until patent expiry support premium pricing.
-
How will biosimilars impact the market after patent loss?
They are expected to enter around 2027-2028, likely reducing prices by 20-50%, and capturing a significant share.
-
Are there regional differences in pricing?
Yes. U.S. prices are generally higher, with rebates and negotiations reducing actual payer costs, while European prices are regulated and lower.
-
Can expanding indications sustain revenue growth?
Yes. Additional approved uses can offset losses from biosimilar competition if they capture new patient segments.
-
What factors influence future pricing trends?
Patent status, biosimilar development, reimbursement policies, and market demand for new indications.
References
- Novartis Financial Reports 2022.
- IQVIA, "The Market for Biologic Therapies," 2022.
- EvaluatePharma, "Top Drugs in Psoriasis," 2022.
- U.S. Medicaid and Medicare reimbursement data, 2022.
- Industry analysis from GoodRx Healthcare, 2023.
